首页|期刊导航|现代中医药|十味咳喘方治疗慢性阻塞性肺疾病急性加重期痰湿阻肺证临床研究

十味咳喘方治疗慢性阻塞性肺疾病急性加重期痰湿阻肺证临床研究OA

Curative Efficacy of Shiwei Kechuan Prescription in Treating Exacerbation of Chronic Obstructive Pulmonary Disease with Syndrome of Phlegm-Dampness

中文摘要英文摘要

目的 观察十味咳喘方治疗慢性阻塞性肺疾病急性加重(acute exacerbation of chronic obstructive pulmo-nary disease,AECOPD)痰湿阻肺证的有效性及安全性.方法 选择 2024 年 6 月-2024 年 12 月于四川省第二中医医院肺病科收治的 AECOPD 痰湿阻肺证患者作为研究对象,采用随机数字表法分为治疗组与对照组,治疗组给予西医基础治疗加口服十味咳喘方(颗粒剂),对照组给予西医基础治疗加口服乙酰半胱氨酸颗粒,疗程为2 w.比较两组患者的 24 h 痰液积分、中医证候总有效率、中医症状积分、慢性阻塞性肺疾病评估测试评分(mMRC)、改良版英国医学研究委员会呼吸困难量表评分(CAT)变化情况以及药物的安全性.结果 治疗2 w 后,治疗组24 h 痰量积分较对照组有明显改善(P<0.05),治疗组中医证候总有效率 90.32%,优于对照组的 67.74%(P<0.05);治疗组患者咳嗽喘息积分较对照组有明显改善(P<0.05);治疗组患者痰多痰黏积分较对照组有明显改善(P<0.05),治疗组患者胸闷积分较对照组有明显改善(P<0.05);治疗组患者气短积分较对照组有明显改善(P<0.05),治疗组患者腹胀纳呆积分较对照组有明显改善(P<0.05);治疗组患者 mMRC 评分较对照组有明显改善(P<0.05);治疗组患者 CAT 评分较对照组有明显改善(P<0.05).治疗结束后,治疗组未见明显不良反应.结论 十味咳喘方联合西医基础治疗可明显改善慢性阻塞性肺疾病急性加重期痰湿阻肺证症状,并且具有良好的安全性,有临床应用价值.

Objective To evaluate the efficacy and safety of Shiwei Kechuan Prescription(SWKCP)in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)presenting with phlegm-dampness syndrome.Methods Patients diagnosed with AECOPD and phlegm-dampness syndrome were enrolled from the inpatient department of Pulmonology at Sichuan Second Hospital of Traditional Chinese Medicine between June 2024 and December 2024.The patients were randomly assigned to either an treatment group or a control group.Both groups received conventional Western medicine treatment.In addition,the treatment group was administered SWKCP(granules),while the control group received acetylcysteine.The treatment duration was two weeks.The evaluation parameters included the both 24-hour sputum volume and sputum viscosity,the effective rate according to TCM criteria,along with changes in symptom scores,the modified Medical Research Council(mMRC)score,and the COPD Assessment Test(CAT)score.Safety served as an additional efficacy endpoint.Results After two weeks of treatment,both 24-hour sputum volume and sputum viscosity were also significantly improved in the treatment group compared to the control group(P<0.05).the TCM syndrome effective rate in the treatment group(90.32%)was significantly higher than that in the control group(67.74%)(P<0.05).Compared with the control group,the treatment group showed markedly greater improvements in the following scores:cough and wheezing(P<0.05),phlegm and mucus(P<0.05),chest tightness(P<0.05),shortness of breath(P<0.05),and abdominal distension(P<0.05).Additionally,the mMRC score improved more substantially in the treatment group(P<0.05),as did the CAT score(P<0.05).No obvious adverse reactions were observed in the treatment group after treatment.Conclusion The combination of SWKCP with conventional Western medicine treatment significantly improves symptoms of phlegm-dampness syndrome in patients with AECOPD,demonstrating favorable safety and clinical application value.

刘若阳;余梦瑶;董慧君;罗霞;余德海;李修元;王腾飞;林娟;党思捷;李芳;谭君花;王程;符阿红

四川省第二中医医院,四川 成都 610031四川省中医药科学院,四川 成都 610042四川省第二中医医院,四川 成都 610031四川省中医药科学院,四川 成都 610042四川省第二中医医院,四川 成都 610031四川省第二中医医院,四川 成都 610031四川省第二中医医院,四川 成都 610031四川省第二中医医院,四川 成都 610031四川省第二中医医院,四川 成都 610031四川省中医药科学院,四川 成都 610042四川省第二中医医院,四川 成都 610031四川省第二中医医院,四川 成都 610031四川省第二中医医院,四川 成都 610031

医药卫生

十味咳喘方慢性阻塞性肺疾病急性加重期痰湿阻肺证痰量和痰液黏稠度气道高分泌

exacerbation of chronic obstructive pulmonary diseasesyndrome of phlegm-dampnessShiwei Kechuan Decoctionsputum volume and sputum viscosityarway hypersecretion

《现代中医药》 2026 (5)

114-121,8

四川省中医药管理局科学技术研究专项课题(2023zd006)四川省科技厅川渝科技创新合作计划(2024YFHSZ0084)

10.13424/j.cnki.mtcm.2026.05.019

评论